Statins and hemoperfusion improve 28-day survival in septic shock patients

Tsukasa Nakamura, Eiichi Sato, Nobuharu Fujiwara, Yasuhiro Kawagoe, Sayaka Maeda, Hiroyoshi Inoue, Sho Ichi Yamagishi

Research output: Contribution to journalArticle


Uncontrolled inflammation and endotoxin play a central role in septic shock. Statins may possess anti-inflammatory properties, and removal of endotoxin by hemoperfusion with polymyxin B-immobilized fiiber (PMX-F) could have favorable effects on sepsis. We examined retrospectively whether pre-existing statin and hemoperfusion with PMX-F at the time of admission were separately and independently associated with decreased overall 28-day mortality in septic shock patients. Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. All patients underwent a complete history and physical examination, determination of blood chemistries. Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX-F and HDL-cholesterol were independently correlated to 28-day survival in septic shock patients (R 2=0.464). Our present study suggests that pre-existing statin use and hemoperfusion with PMX-F may separately and independently contribute to blunt the process of septic shock.

Original languageEnglish
Pages (from-to)475-480
Number of pages6
JournalCentral European Journal of Medicine
Issue number4
Publication statusPublished - 2012 Aug 1


  • Inflammation
  • PMX-F
  • Septic shock
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Statins and hemoperfusion improve 28-day survival in septic shock patients'. Together they form a unique fingerprint.

  • Cite this

    Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Maeda, S., Inoue, H., & Yamagishi, S. I. (2012). Statins and hemoperfusion improve 28-day survival in septic shock patients. Central European Journal of Medicine, 7(4), 475-480.